Antiviral agents /
This new volume of Advances in Pharmacology explores the current state of antiviral agents. Chapters cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV. With a variety of chapters and the best authors in the field, the volume is an essential...
| Other Authors: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
San Diego, Calif. :
Academic Press,
c2013
San Diego, CA : Academic Press, an imprint of Elsevier, 2013 |
| Series: | Advances in pharmacology (San Diego, Calif.) ;
volume sixty seven |
| Subjects: |
| LEADER | 05407nam a2200469 i 4500 | ||
|---|---|---|---|
| 001 | 17983ed1-fd0d-45da-80ae-232ac8fc40bc | ||
| 005 | 20240204000000.0 | ||
| 008 | 140415s2013 cauad ob 001 0 eng d | ||
| 020 | |a 0-12-405537-0 | ||
| 035 | |a (EXLCZ)992550000001106182 | ||
| 035 | |a (MiFhGG)GVRL6ZRT | ||
| 035 | |a (OCoLC)854681015 | ||
| 040 | |a MiFhGG |b eng |c MiFhGG |e rda |e pn | ||
| 041 | |a eng | ||
| 050 | 4 | |a RM411 |b .A58 2013 | |
| 082 | 0 | 0 | |a 615.1 |
| 245 | 0 | 0 | |a Antiviral agents / |c edited by Erik De Clercq, Rega Institute for Medical Research, KU Leuven, 10 Minderbroedersstraat, B-3000 Leuven, Belgium |
| 260 | |a San Diego, Calif. : |b Academic Press, |c c2013 | ||
| 264 | 1 | |a San Diego, CA : |b Academic Press, an imprint of Elsevier, |c 2013 | |
| 300 | |a 1 online resource (xiv, 369 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt | ||
| 337 | |a computer |b c | ||
| 338 | |a online resource |b cr | ||
| 490 | 1 | |a Advances in Pharmacology ; |v Volume 67 | |
| 500 | |a "ISSN: 1054-3589." | ||
| 504 | |a Includes bibliographical references at the end of each chapters and indexes | ||
| 505 | 0 | |a Front Cover; Antiviral Agents; Copyright; Contents; Preface; References; Contributors; Chapter One: Antiviral Agents for Herpes Simplex Virus; 1. Introduction; 1.1. The Herpesviridae; 1.1.1. HSV-1 and HSV-2 are closely related viruses; 1.2. Rarer forms of HSV disease; 2. Historical Overview: Therapies for HSV Infections; 2.1. Early progress toward highly selective and effective antivirals; 2.2. ACV and PCV: Preclinical evaluations; 2.2.1. Mechanism for latency efficacy: A hypothesis; 2.3. ACV, PCV, and their prodrugs: Clinical studies; 2.3.1. Herpes labialis (cold sores) caused by HSV-1 | |
| 505 | 8 | |a 2.3.2. Genital herpes2.3.2.1. Primary genital herpes (usually caused by HSV-2, sometimes caused by HSV-1); 2.3.2.2. Therapy for recurrent genital herpes-Episodic therapy; 2.3.2.3. Therapy for recurrent genital herpes-Suppressive therapy; 3. Clinical Experience with ACV, VACV, and FCV Through Two Decades; 3.1. Clinical benefit; 3.2. New opportunities for FCV and VACV?; 4. Antiviral Drug Resistance; 4.1. Introduction; 4.2. Drug-resistant strains tested in HSV laboratory animal infection models; 4.3. HSV drug resistance in ophthalmic infections; 4.4. Drug resistance in immunocompromised patients | |
| 505 | 8 | |a 3.1. Nucleotide phosphoramidate prodrugs3.2. HepDirect liver-targeting prodrugs; 3.3. 3',5'-Cyclic phosphate nucleotide prodrugs; 3.4. Phosphate and phosphonate ester prodrugs; 4. Conclusion; Conflict of Interest; References; Chapter Three: HIV Integrase Inhibitors: 20-Year Landmark and Challenges; 1. Introduction; 2. Requirement of IN for HIV Replication; 3. IN Structure; 4. The INSTIs; 5. Challenges; 5.1. Resistance to INSTIs; 5.2. Long-term safety and tolerance for INSTIs; 5.3. Economical considerations and prophylactic treatments; 5.4. Novel INIs targeting IN outside its catalytic site | |
| 505 | 8 | |a 4.2. Treatment of rare but important side effects caused by the VZV vaccine | |
| 505 | 8 | |a 4.5. Concept of genetic barrier5. Novel Approaches to HSV Chemotherapy; 5.1. Nucleoside analogues in combination with anti-inflammatory compounds; 5.2. Helicase-primase: A new selective virus target for HSV; 5.3. TK bypass; 6. Prospects for Novel Antiviral Compounds and Vaccines; 6.1. Difficulties facing novel compounds; 6.2. Lack of progress in the control of HSV by means of immunization; 7. Conclusion; Conflict of Interest; References; Chapter Two: Nucleotide Prodrugs for the Treatment of HCV Infection; 1. Introduction; 2. Nucleoside Inhibitors; 3. Nucleotide Prodrugs | |
| 505 | 8 | |a 5.4.1. The LEDGINs5.4.2. Peptides targeting the LEDGF/p75 binding site; 5.4.3. Inhibitors targeting other cellular cofactors; 5.4.4. Allosteric inhibitors of IN; 5.5. Chromatin and DNA repair cofactors completing integration; 6. Conclusion; Conflict of Interest; References; Chapter Four: Advances in the Treatment of Varicella-Zoster Virus Infections; 1. Introduction; 2. Vaccination Strategies and Postexposure Prophylaxis; 3. Existing Antiviral Treatments; 4. Medical Need for New Anti-VZV Agents; 4.1. Management of PHN and other complications | |
| 520 | |a This new volume of Advances in Pharmacology explores the current state of antiviral agents. Chapters cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. Explores the current state of anti-viral agentsChapters cover a variety of topics such as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSVWith the | ||
| 546 | |a English | ||
| 588 | |a Description based on online resource; title from title page (ebrary, viewed August 13, 2013) | ||
| 650 | 0 | |a Antiviral agents | |
| 700 | 1 | |a De Clercq, Erik, |e editor | |
| 760 | 0 | |t Advances in pharmacology |w (CKB)954927720456 |w (DLC)2005215191 |x 1557-8925 | |
| 776 | |z 0-12-405880-9 | ||
| 776 | |z 1-299-75290-X | ||
| 830 | 0 | |a Advances in pharmacology (San Diego, Calif.) ; |v volume sixty seven | |
| 999 | 1 | 0 | |i 17983ed1-fd0d-45da-80ae-232ac8fc40bc |l 9977122716203681 |s US-PU |m antiviral_agents___________________________________________________________2013_______acadea___________________________________________________________________________e |